Therapeutic RNA for Lung Cancer
JP2024537298A5Pending Publication Date: 2025-10-22BIONTECH SE +1
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- JP2024521854
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-01-05
- Filing Date
- 2022-10-10
- Publication Date
- 2025-10-22
AI Technical Summary
Technical Problem
Current treatments for lung cancer, particularly non-small cell lung cancer (NSCLC), lack effective methods to reduce tumor size, prevent metastasis, and extend survival time while overcoming immune tolerance mechanisms.
Method used
Administration of therapeutic RNA encoding tumor antigens, combined with structural elements and immune tolerance-disrupting sequences, formulated as RNA-lipoplexes to stimulate a robust T cell-mediated immune response.
Benefits of technology
The approach reduces tumor size, prolongs time to disease progression, and enhances survival by inducing a potent anti-cancer immune response, effectively targeting NSCLC.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 00000096_0000 
Figure 00000096_0001 
Figure 00000097_0000
Abstract
The present disclosure relates to the field of RNA for treating lung cancer, particularly non-small cell lung cancer (NSCLC). Lung cancer is the third most common malignant tumor in women and the second most common malignant tumor in men. NSCLC accounts for about 85% of all lung cancers. Disclosed herein are compositions, uses, and methods for treating lung cancer. Administration of therapeutic RNA disclosed herein to patients with lung cancer can reduce tumor size, prolong time to progressive disease, and / or protect against tumor metastasis and / or recurrence, ultimately prolonging survival time.
Need to check novelty before this filing date? Find Prior Art